𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept

✍ Scribed by Christopher Sacher; Andrea Rubbert; Cathrin König; Karin Scharffetter-Kochanek; Thomas Krieg; Nicolas Hunzelmann

Book ID
117845170
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
77 KB
Volume
46
Category
Article
ISSN
1097-6787

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Life-threatening histoplasmosis complica
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
✍ Jong-Hoon Lee; Nancy R. Slifman; Sharon K. Gershon; Evelyne T. Edwards; William 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract ## Objective Two tumor necrosis factor α (TNFα) antagonists were recently licensed in the US. Infliximab was licensed in 1998 for the treatment of Crohn's disease (CD), and since 1999, it has been licensed in combination with methotrexate for treatment of rheumatoid arthritis (RA). Eta